Trial Profile
A phase II study of Temodal (sch 52365; temozolomide, ind#52797) in children and adolescents with recurrent central nervous system (CNS) tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2005
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- 11 Dec 2005 New trial record.